Tuberculosis is often treated as a medical relic, yet it still kills more than a million people every year and remains one of the world’s deadliest infectious diseases. In response, scientists have begun turning to an unexpected ally: a miniature, breathing replica of human lung tissue built on a transparent chip. By infecting this engineered organ with the same bacteria that ravage real lungs, they are trying to expose the disease’s hidden weaknesses and design more precise treatments.
Instead of relying solely on animals or static cell cultures, researchers are now recreating the delicate air sacs of the lung in a controlled device that can inhale, exhale, and respond to infection. I see this shift as more than a technical upgrade; it is a conceptual break from the idea that we must wait for disease to strike patients before we can truly understand it.
The enduring threat of tuberculosis
For all the progress of modern medicine, tuberculosis, or TB, still behaves like an unmitigated disaster. It kills more than a million people each year and continues to rank among the leading infectious causes of death worldwide, even though it is often misidentified as a disease of the past. When I look at those numbers, I see a pathogen that has quietly outlasted generations of antibiotics and public health campaigns, exploiting crowded cities, fragile health systems, and the slow churn of drug development to maintain its grip on human lungs.
That persistence is precisely why Jan and other specialists have turned to unconventional tools. In their view, the old model of testing TB drugs in animals and then hoping the results translate to people is no longer enough, particularly as drug resistant strains spread. By building a human lung environment on a chip and then deliberately infecting it with Mycobacterium tuberculosis, scientists are trying to compress years of clinical uncertainty into a controlled experiment that can be repeated, refined, and compared across different patients. The goal, as described in work on TB remains, is to turn a global emergency into a problem that can be dissected at micrometer scale.
How a breathing lung-on-chip is built
To understand why this approach is so powerful, I first need to picture the device itself. Researchers at the Francis Crick Institute and AlveoliX have created a human lung model that uses stem cells taken from a single donor to form both the air facing and blood facing surfaces of the alveoli. These genetically identical cells are arranged on a flexible membrane that can be rhythmically stretched, so the chip does not just sit in a dish, it actually breathes. By using one person’s cells to populate the entire structure, the team can study how a specific individual’s lung tissue might respond to infection or therapy, as described in work on Researchers at the Francis Crick Institute and their collaborators.
Other groups have pushed this concept further by refining the architecture of the air sacs. A system known as iLoC, developed by RESEARCHERS earlier this year, is designed to model human alveoli with high fidelity, including the thin barrier between air and blood and the mechanical forces of breathing. In my reading, the key innovation is not just the microfluidic channels or the silicone membranes, but the way these platforms integrate immune cells, airflow, and bloodlike perfusion to mimic the dynamic environment where TB bacteria actually live. The iLoC platform, described in detail in reports on innovative lung-on-chip technology, shows how far this field has moved beyond flat cell layers on plastic.
Infecting the chip with TB
Once a chip can breathe, the next step is to challenge it with the same microbes that torment human lungs. Scientists made this lung-on-a-chip breathe, then they gave it TB by introducing Mycobacterium tuberculosis into the air channel and watching how the bacteria interacted with the genetically identical cells lining the alveolar surface. Instead of a crude snapshot, they could track how the infection spread, how immune cells responded, and how the tissue architecture changed over time. Reports on this work describe how the researchers deliberately avoided mixing cells from multiple donors, relying instead on a single source of stem cells so that any differences in outcome could be traced to the pathogen or the treatment, as detailed in coverage of scientists made this lung-on-a-chip breathe.
In parallel, Jan and colleagues have framed this infection strategy as a way to personalize TB care. By infecting a chip built from one person’s cells, they can test how that individual’s lung tissue tolerates different drug combinations or dosing schedules before exposing the patient to those regimens. The same logic underpins a broader push toward personalized medicine, in which a new lung-on-chip model consisting solely of genetically identical cells from a single person is used to explore disease mechanisms and drug responses. That approach, described in work on a single-donor lung-on-chip, aligns with Jan’s effort to move TB research away from one size fits all protocols and toward tailored interventions that reflect each patient’s biology.
From lab curiosity to clinical tool
For this technology to matter beyond the lab, it has to capture the complexity of breathing lungs under real mechanical stress. Scientists have already demonstrated a breathing lung-on-chip model built using only one person’s cells, in which the tissue is cyclically stretched to mimic inhalation and exhalation. That mechanical stress is not a cosmetic detail; it shapes how cells sense pathogens, secrete signaling molecules, and respond to drugs. Reports on this work emphasize that, for the first time, a breathing lung model has been created from genetically identical cells that experience realistic motion, as described in coverage of scientists build this breathing chip and in technical descriptions of how mechanical stress is vital for realistic modeling.